Hepatitis B: Who and when to treat?

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Current hepatitis B virus (HBV) treatments focus on inhibiting viral replication rather than achieving complete eradication.
• The primary therapeutic goal is sustained suppression of HBV DNA and normalization of alanine aminotransferase (ALT) levels.

Purpose of the Study:

• To outline current evidence-based indications for initiating antiviral therapy in chronic hepatitis B.
• To define criteria for prophylactic treatment in specific patient populations at risk of HBV recurrence or reactivation.
• To emphasize the importance of individualized treatment decisions based on patient-specific factors.

Main Methods:

• Review of current clinical guidelines and scientific literature on hepatitis B management.
• Analysis of patient criteria including HBV DNA levels, ALT values, liver stiffness (kPa), histological findings, and patient history (e.g., family history of cirrhosis/HCC, HBeAg status).
• Identification of specific scenarios necessitating prophylactic treatment, such as liver transplantation, pregnancy, immunosuppression, co-infections, and healthcare workers.

Main Results:

• Treatment is generally recommended for chronic hepatitis B patients with HBV DNA >2000 IU/mL and elevated ALT or moderate histological lesions.
• All patients with cirrhosis and detectable HBV DNA require treatment.
• Specific criteria involving higher viral loads, liver stiffness, family history, HBeAg status, and age guide treatment initiation even with normal ALT or histology.

Conclusions:

• Treatment indications are based on achieving viral inhibition and ALT normalization, not eradication.
• Prophylactic treatment is crucial in liver transplant recipients, pregnant women with high viremia, and immunocompromised individuals to prevent recurrence or reactivation.
• Future advancements enabling HBV eradication or HBsAg clearance could alter current treatment paradigms.